Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry. (PubMed, J Clin Lipidol) - Aug 19, 2026 - P | "LOWER supports lomitapide's long-term effectiveness and safety for up to 11 years, enabling substantial LDL-C reductions and treatment goal achievement in HoFH with a manageable safety profile. Tentative evidence of reduced MACE during lomitapide treatment warrants further investigation."
Journal • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders
|
|
Dirk J Blom; Dominique Larrey; James Underberg; Lukas Makris; Sallyann O'Brien
|